APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Immune Thrombocytopenia Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Immune Thrombocytopenia Drugs Market Outlook and Growth Opportunities 2026

Report ID 174002000422 December 2025195 pages

Choose your research edition.

Industry ResearchImmune Thrombocytopenia Drugs Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Immune Thrombocytopenia Drugs Industry Growth and Trends Forecast to 203285 pages · $3,450 USDMarket StructureGlobal Immune Thrombocytopenia Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Immune Thrombocytopenia Drugs Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Immune Thrombocytopenia Drugs Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Immune Thrombocytopenia Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Immune Thrombocytopenia Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Immune Thrombocytopenia Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Immune Thrombocytopenia Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Immune Thrombocytopenia Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Immune Thrombocytopenia Drugs market include Novartis AG, Merck & Co., Inc., Amgen Inc., Rigel Pharmaceuticals Inc., Horizon Therapeutics Plc and CSL Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Immune Thrombocytopenia Drugs market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Immune Thrombocytopenia Drugs and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Immune Thrombocytopenia Drugs revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Immune Thrombocytopenia Drugs market.

Immune Thrombocytopenia Drugs Segment by Company

Novartis AG

Merck & Co., Inc.

Amgen Inc.

Rigel Pharmaceuticals Inc.

Horizon Therapeutics Plc

CSL Ltd.

Immune Thrombocytopenia Drugs Segment by Type

Intravenous Immunoglobins (IVIGs)

Corticosteroids

Thrombopoietin Receptor Agonists (TPO-RAs)

Other Drugs

Immune Thrombocytopenia Drugs Segment by Application

Hospitals and Diagnostic Centers

Academic Institutes and Research Organizations

Biotechnology and Pharmaceutical Companies

Immune Thrombocytopenia Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Immune Thrombocytopenia Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Immune Thrombocytopenia Drugs key companies, revenue, market share, and recent developments.

3. To split the Immune Thrombocytopenia Drugs breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Immune Thrombocytopenia Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Immune Thrombocytopenia Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Immune Thrombocytopenia Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Immune Thrombocytopenia Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Immune Thrombocytopenia Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Immune Thrombocytopenia Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Immune Thrombocytopenia Drugs industry.

Chapter 3: Detailed analysis of Immune Thrombocytopenia Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Immune Thrombocytopenia Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Immune Thrombocytopenia Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Immune Thrombocytopenia Drugs Industry Trends Table 2. Immune Thrombocytopenia Drugs Industry Drivers Table 3. Immune Thrombocytopenia Drugs Industry Opportunities and Challenges Table 4. Immune Thrombocytopenia Drugs Industry Restraints Table 5. Global Immune Thrombocytopenia Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Immune Thrombocytopenia Drugs Revenue Share by Company (2021-2026) Table 7. Global Immune Thrombocytopenia Drugs Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Immune Thrombocytopenia Drugs Key Company Manufacturing Base & Headquarters Table 9. Global Immune Thrombocytopenia Drugs Company, Product Type & Application Table 10. Global Immune Thrombocytopenia Drugs Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Immune Thrombocytopenia Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Intravenous Immunoglobins (IVIGs) Table 15. Significant Companies of Corticosteroids Table 16. Significant Companies of Thrombopoietin Receptor Agonists (TPO-RAs) Table 17. Significant Companies of Other Drugs Table 18. Global Immune Thrombocytopenia Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Immune Thrombocytopenia Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Immune Thrombocytopenia Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Immune Thrombocytopenia Drugs Sales Value Share by Type (2021-2026) Table 22. Global Immune Thrombocytopenia Drugs Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Hospitals and Diagnostic Centers Table 24. Significant Companies of Academic Institutes and Research Organizations Table 25. Significant Companies of Biotechnology and Pharmaceutical Companies Table 26. Global Immune Thrombocytopenia Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Immune Thrombocytopenia Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Immune Thrombocytopenia Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Immune Thrombocytopenia Drugs Sales Value Share by Application (2021-2026) Table 30. Global Immune Thrombocytopenia Drugs Sales Value Share by Application (2027-2032) Table 31. Global Immune Thrombocytopenia Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Immune Thrombocytopenia Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Immune Thrombocytopenia Drugs Sales Value Share by Region (2021-2026) Table 34. Global Immune Thrombocytopenia Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Immune Thrombocytopenia Drugs Sales Value Share by Region (2027-2032) Table 36. Global Immune Thrombocytopenia Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Immune Thrombocytopenia Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Immune Thrombocytopenia Drugs Sales Value Market Share by Country (2021-2026) Table 39. Global Immune Thrombocytopenia Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Immune Thrombocytopenia Drugs Sales Value Market Share by Country (2027-2032) Table 41. Novartis AG Company Information Table 42. Novartis AG Business Overview Table 43. Novartis AG Immune Thrombocytopenia Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Novartis AG Immune Thrombocytopenia Drugs Product Portfolio Table 45. Novartis AG Recent Development Table 46. Merck & Co., Inc. Company Information Table 47. Merck & Co., Inc. Business Overview Table 48. Merck & Co., Inc. Immune Thrombocytopenia Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Merck & Co., Inc. Immune Thrombocytopenia Drugs Product Portfolio Table 50. Merck & Co., Inc. Recent Development Table 51. Amgen Inc. Company Information Table 52. Amgen Inc. Business Overview Table 53. Amgen Inc. Immune Thrombocytopenia Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Amgen Inc. Immune Thrombocytopenia Drugs Product Portfolio Table 55. Amgen Inc. Recent Development Table 56. Rigel Pharmaceuticals Inc. Company Information Table 57. Rigel Pharmaceuticals Inc. Business Overview Table 58. Rigel Pharmaceuticals Inc. Immune Thrombocytopenia Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Rigel Pharmaceuticals Inc. Immune Thrombocytopenia Drugs Product Portfolio Table 60. Rigel Pharmaceuticals Inc. Recent Development Table 61. Horizon Therapeutics Plc Company Information Table 62. Horizon Therapeutics Plc Business Overview Table 63. Horizon Therapeutics Plc Immune Thrombocytopenia Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Horizon Therapeutics Plc Immune Thrombocytopenia Drugs Product Portfolio Table 65. Horizon Therapeutics Plc Recent Development Table 66. CSL Ltd. Company Information Table 67. CSL Ltd. Business Overview Table 68. CSL Ltd. Immune Thrombocytopenia Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. CSL Ltd. Immune Thrombocytopenia Drugs Product Portfolio Table 70. CSL Ltd. Recent Development Table 71. Research Programs/Design for This Report Table 72. Authors List of This Report Table 73. Secondary Sources Table 74. Primary Sources List of Figures Figure 1. Immune Thrombocytopenia Drugs Product Image Figure 2. Global Immune Thrombocytopenia Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Immune Thrombocytopenia Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Immune Thrombocytopenia Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Intravenous Immunoglobins (IVIGs) Image Figure 8. Corticosteroids Image Figure 9. Thrombopoietin Receptor Agonists (TPO-RAs) Image Figure 10. Other Drugs Image Figure 11. Global Immune Thrombocytopenia Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Immune Thrombocytopenia Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Immune Thrombocytopenia Drugs Sales Value Share by Type (2021-2032) Figure 14. Hospitals and Diagnostic Centers Image Figure 15. Academic Institutes and Research Organizations Image Figure 16. Biotechnology and Pharmaceutical Companies Image Figure 17. Global Immune Thrombocytopenia Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Immune Thrombocytopenia Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Immune Thrombocytopenia Drugs Sales Value Share by Application (2021-2032) Figure 20. Global Immune Thrombocytopenia Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Immune Thrombocytopenia Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Immune Thrombocytopenia Drugs Sales Value (2021-2032) & (US$ Million) Figure 23. North America Immune Thrombocytopenia Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Immune Thrombocytopenia Drugs Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Immune Thrombocytopenia Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Immune Thrombocytopenia Drugs Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Immune Thrombocytopenia Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Immune Thrombocytopenia Drugs Sales Value (2021-2032) & (US$ Million) Figure 29. South America Immune Thrombocytopenia Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Immune Thrombocytopenia Drugs Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Immune Thrombocytopenia Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Immune Thrombocytopenia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Immune Thrombocytopenia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Immune Thrombocytopenia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Immune Thrombocytopenia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Immune Thrombocytopenia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Immune Thrombocytopenia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Immune Thrombocytopenia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Immune Thrombocytopenia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Immune Thrombocytopenia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Immune Thrombocytopenia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Immune Thrombocytopenia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Immune Thrombocytopenia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Immune Thrombocytopenia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Immune Thrombocytopenia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Immune Thrombocytopenia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Immune Thrombocytopenia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Immune Thrombocytopenia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Immune Thrombocytopenia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Immune Thrombocytopenia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Immune Thrombocytopenia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Immune Thrombocytopenia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Immune Thrombocytopenia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Immune Thrombocytopenia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Immune Thrombocytopenia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Immune Thrombocytopenia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Immune Thrombocytopenia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Immune Thrombocytopenia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Immune Thrombocytopenia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Immune Thrombocytopenia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Immune Thrombocytopenia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Immune Thrombocytopenia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Immune Thrombocytopenia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Immune Thrombocytopenia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Immune Thrombocytopenia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Immune Thrombocytopenia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Immune Thrombocytopenia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Immune Thrombocytopenia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Immune Thrombocytopenia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Immune Thrombocytopenia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Immune Thrombocytopenia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Immune Thrombocytopenia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Immune Thrombocytopenia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Immune Thrombocytopenia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Immune Thrombocytopenia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Immune Thrombocytopenia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Immune Thrombocytopenia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Immune Thrombocytopenia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Immune Thrombocytopenia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Immune Thrombocytopenia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Immune Thrombocytopenia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Immune Thrombocytopenia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Immune Thrombocytopenia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Immune Thrombocytopenia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Immune Thrombocytopenia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Immune Thrombocytopenia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Immune Thrombocytopenia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Immune Thrombocytopenia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Immune Thrombocytopenia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Immune Thrombocytopenia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Immune Thrombocytopenia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Immune Thrombocytopenia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Immune Thrombocytopenia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Immune Thrombocytopenia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Immune Thrombocytopenia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Immune Thrombocytopenia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Immune Thrombocytopenia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Immune Thrombocytopenia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Immune Thrombocytopenia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Immune Thrombocytopenia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Immune Thrombocytopenia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Immune Thrombocytopenia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Immune Thrombocytopenia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Immune Thrombocytopenia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Immune Thrombocytopenia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Immune Thrombocytopenia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Immune Thrombocytopenia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Immune Thrombocytopenia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Immune Thrombocytopenia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Immune Thrombocytopenia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Immune Thrombocytopenia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Immune Thrombocytopenia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Immune Thrombocytopenia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Immune Thrombocytopenia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Immune Thrombocytopenia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Intravenous Immunoglobins (IVIGs)
  • Corticosteroids
  • Thrombopoietin Receptor Agonists (TPO-RAs)
  • Other Drugs
Applications
  • Hospitals and Diagnostic Centers
  • Academic Institutes and Research Organizations
  • Biotechnology and Pharmaceutical Companies
Companies covered
  • Novartis AG
  • Merck & Co., Inc.
  • Amgen Inc.
  • Rigel Pharmaceuticals Inc.
  • Horizon Therapeutics Plc
  • CSL Ltd.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Immune Thrombocytopenia Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Immune Thrombocytopenia Drugs Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Immune Thrombocytopenia Drugs Market Dynamics
  1. 2.1 Immune Thrombocytopenia Drugs Industry Trends
  2. 2.2 Immune Thrombocytopenia Drugs Industry Drivers
  3. 2.3 Immune Thrombocytopenia Drugs Industry Opportunities and Challenges
  4. 2.4 Immune Thrombocytopenia Drugs Industry Restraints
3 Immune Thrombocytopenia Drugs Market by Company
  1. 3.1 Global Immune Thrombocytopenia Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Immune Thrombocytopenia Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Immune Thrombocytopenia Drugs Company Ranking (2024-2026)
  4. 3.4 Global Immune Thrombocytopenia Drugs Company Manufacturing Base and Headquarters
  5. 3.5 Global Immune Thrombocytopenia Drugs Company Product Type and Application
  6. 3.6 Global Immune Thrombocytopenia Drugs Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Immune Thrombocytopenia Drugs Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Immune Thrombocytopenia Drugs Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Immune Thrombocytopenia Drugs Market by Type
  1. 4.1 Immune Thrombocytopenia Drugs Type Introduction
  2. 4.1.1 Intravenous Immunoglobins (IVIGs)
  3. 4.1.2 Corticosteroids
  4. 4.1.3 Thrombopoietin Receptor Agonists (TPO-RAs)
  5. 4.1.4 Other Drugs
  6. 4.2 Global Immune Thrombocytopenia Drugs Sales Value by Type
  7. 4.2.1 Global Immune Thrombocytopenia Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Immune Thrombocytopenia Drugs Sales Value by Type (2021-2032)
  9. 4.2.3 Global Immune Thrombocytopenia Drugs Sales Value Share by Type (2021-2032)
5 Immune Thrombocytopenia Drugs Market by Application
  1. 5.1 Immune Thrombocytopenia Drugs Application Introduction
  2. 5.1.1 Hospitals and Diagnostic Centers
  3. 5.1.2 Academic Institutes and Research Organizations
  4. 5.1.3 Biotechnology and Pharmaceutical Companies
  5. 5.2 Global Immune Thrombocytopenia Drugs Sales Value by Application
  6. 5.2.1 Global Immune Thrombocytopenia Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Immune Thrombocytopenia Drugs Sales Value by Application (2021-2032)
  8. 5.2.3 Global Immune Thrombocytopenia Drugs Sales Value Share by Application (2021-2032)
6 Immune Thrombocytopenia Drugs Regional Value Analysis
  1. 6.1 Global Immune Thrombocytopenia Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Immune Thrombocytopenia Drugs Sales Value by Region (2021-2032)
  3. 6.2.1 Global Immune Thrombocytopenia Drugs Sales Value by Region: 2021-2026
  4. 6.2.2 Global Immune Thrombocytopenia Drugs Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Immune Thrombocytopenia Drugs Sales Value (2021-2032)
  7. 6.3.2 North America Immune Thrombocytopenia Drugs Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Immune Thrombocytopenia Drugs Sales Value (2021-2032)
  10. 6.4.2 Europe Immune Thrombocytopenia Drugs Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Immune Thrombocytopenia Drugs Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Immune Thrombocytopenia Drugs Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Immune Thrombocytopenia Drugs Sales Value (2021-2032)
  16. 6.6.2 South America Immune Thrombocytopenia Drugs Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Immune Thrombocytopenia Drugs Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Immune Thrombocytopenia Drugs Sales Value Share by Country, 2025 VS 2032
7 Immune Thrombocytopenia Drugs Country-level Value Analysis
  1. 7.1 Global Immune Thrombocytopenia Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Immune Thrombocytopenia Drugs Sales Value by Country (2021-2032)
  3. 7.2.1 Global Immune Thrombocytopenia Drugs Sales Value by Country (2021-2026)
  4. 7.2.2 Global Immune Thrombocytopenia Drugs Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Immune Thrombocytopenia Drugs Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Immune Thrombocytopenia Drugs Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Immune Thrombocytopenia Drugs Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Immune Thrombocytopenia Drugs Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Immune Thrombocytopenia Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Immune Thrombocytopenia Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Immune Thrombocytopenia Drugs Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Immune Thrombocytopenia Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Immune Thrombocytopenia Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Immune Thrombocytopenia Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Immune Thrombocytopenia Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Immune Thrombocytopenia Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Immune Thrombocytopenia Drugs Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Immune Thrombocytopenia Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Immune Thrombocytopenia Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Immune Thrombocytopenia Drugs Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Immune Thrombocytopenia Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Immune Thrombocytopenia Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Immune Thrombocytopenia Drugs Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Immune Thrombocytopenia Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Immune Thrombocytopenia Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Immune Thrombocytopenia Drugs Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Immune Thrombocytopenia Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Immune Thrombocytopenia Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Immune Thrombocytopenia Drugs Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Immune Thrombocytopenia Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Immune Thrombocytopenia Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Immune Thrombocytopenia Drugs Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Immune Thrombocytopenia Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Immune Thrombocytopenia Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Immune Thrombocytopenia Drugs Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Immune Thrombocytopenia Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Immune Thrombocytopenia Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Immune Thrombocytopenia Drugs Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Immune Thrombocytopenia Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Immune Thrombocytopenia Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Immune Thrombocytopenia Drugs Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Immune Thrombocytopenia Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Immune Thrombocytopenia Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Immune Thrombocytopenia Drugs Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Immune Thrombocytopenia Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Immune Thrombocytopenia Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Immune Thrombocytopenia Drugs Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Immune Thrombocytopenia Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Immune Thrombocytopenia Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Immune Thrombocytopenia Drugs Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Immune Thrombocytopenia Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Immune Thrombocytopenia Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Immune Thrombocytopenia Drugs Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Immune Thrombocytopenia Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Immune Thrombocytopenia Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Immune Thrombocytopenia Drugs Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Immune Thrombocytopenia Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Immune Thrombocytopenia Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Immune Thrombocytopenia Drugs Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Immune Thrombocytopenia Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Immune Thrombocytopenia Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Immune Thrombocytopenia Drugs Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Immune Thrombocytopenia Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Immune Thrombocytopenia Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Immune Thrombocytopenia Drugs Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Immune Thrombocytopenia Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Immune Thrombocytopenia Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Immune Thrombocytopenia Drugs Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Immune Thrombocytopenia Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Immune Thrombocytopenia Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Immune Thrombocytopenia Drugs Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Immune Thrombocytopenia Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Immune Thrombocytopenia Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Immune Thrombocytopenia Drugs Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Immune Thrombocytopenia Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Immune Thrombocytopenia Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Immune Thrombocytopenia Drugs Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Immune Thrombocytopenia Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Immune Thrombocytopenia Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Immune Thrombocytopenia Drugs Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Immune Thrombocytopenia Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Immune Thrombocytopenia Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Immune Thrombocytopenia Drugs Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Immune Thrombocytopenia Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Immune Thrombocytopenia Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Immune Thrombocytopenia Drugs Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Immune Thrombocytopenia Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Immune Thrombocytopenia Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis AG
  2. 8.1.1 Novartis AG Company Information
  3. 8.1.2 Novartis AG Business Overview
  4. 8.1.3 Novartis AG Immune Thrombocytopenia Drugs Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Novartis AG Immune Thrombocytopenia Drugs Product Portfolio
  6. 8.1.5 Novartis AG Recent Developments
  7. 8.2 Merck & Co., Inc.
  8. 8.2.1 Merck & Co., Inc. Company Information
  9. 8.2.2 Merck & Co., Inc. Business Overview
  10. 8.2.3 Merck & Co., Inc. Immune Thrombocytopenia Drugs Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Merck & Co., Inc. Immune Thrombocytopenia Drugs Product Portfolio
  12. 8.2.5 Merck & Co., Inc. Recent Developments
  13. 8.3 Amgen Inc.
  14. 8.3.1 Amgen Inc. Company Information
  15. 8.3.2 Amgen Inc. Business Overview
  16. 8.3.3 Amgen Inc. Immune Thrombocytopenia Drugs Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Amgen Inc. Immune Thrombocytopenia Drugs Product Portfolio
  18. 8.3.5 Amgen Inc. Recent Developments
  19. 8.4 Rigel Pharmaceuticals Inc.
  20. 8.4.1 Rigel Pharmaceuticals Inc. Company Information
  21. 8.4.2 Rigel Pharmaceuticals Inc. Business Overview
  22. 8.4.3 Rigel Pharmaceuticals Inc. Immune Thrombocytopenia Drugs Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Rigel Pharmaceuticals Inc. Immune Thrombocytopenia Drugs Product Portfolio
  24. 8.4.5 Rigel Pharmaceuticals Inc. Recent Developments
  25. 8.5 Horizon Therapeutics Plc
  26. 8.5.1 Horizon Therapeutics Plc Company Information
  27. 8.5.2 Horizon Therapeutics Plc Business Overview
  28. 8.5.3 Horizon Therapeutics Plc Immune Thrombocytopenia Drugs Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Horizon Therapeutics Plc Immune Thrombocytopenia Drugs Product Portfolio
  30. 8.5.5 Horizon Therapeutics Plc Recent Developments
  31. 8.6 CSL Ltd.
  32. 8.6.1 CSL Ltd. Company Information
  33. 8.6.2 CSL Ltd. Business Overview
  34. 8.6.3 CSL Ltd. Immune Thrombocytopenia Drugs Revenue and Gross Margin (2021-2026)
  35. 8.6.4 CSL Ltd. Immune Thrombocytopenia Drugs Product Portfolio
  36. 8.6.5 CSL Ltd. Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst